+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial

Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial

Annals of Internal Medicine 119(10): 984-991

To study the effect of cytomegalovirus immune globulin (CMVIG) on prevention of cytomegalovirus (CMV) disease and its complications in patients receiving liver transplants. Randomized, multicenter, placebo-controlled, double-blind trial. Four university-affiliated transplant centers in Boston (Boston Center for Liver Transplantation). One hundred forty-one liver transplant recipients completed the study. CMVIG or placebo (1% albumin) given in a dose of 150 mg/kg body weight within 72 hours of the transplant, then at weeks 2, 4, 6, and 8, and at 100 mg/kg at weeks 12 and 16. Patients were observed for 1 year after transplantation for the development of CMV infection, disease, pneumonia, as well as for opportunistic fungal infections, graft survival, and mortality. Weekly cultures were taken of urine, buffy coat, and throat wash for CMV for 2 months, then monthly, and at any clinical illness. Using a Cox proportional hazards model, CMVIG was shown to reduce severe CMV-associated disease (multi-organ CMV disease, CMV pneumonia, or invasive fungal disease associated with CMV infection) from 26% to 12% (relative risk, 0.39; 95% CI, 0.17 to 0.89). When we controlled for the use of monoclonal antibodies to T cells (OKT3), CMVIG use was still protective (relative risk, 0.39; CI, 0.17 to 0.90). Rates of CMV disease were reduced from 31% to 19% (relative risk, 0.56; CI, 0.3 to 1.1) in CMVIG recipients although no effect on rates of CMV infection, graft survival, or patient survival at 1 year were shown. When we controlled for the urgency of transplantation and OKT3 use, a reduction in CMV disease (relative risk, 0.22; CI, 0.06 to 0.81) was shown for globulin recipients for all serologic groups except for the highest risk group (the CMV-seropositive donor, CMV-seronegative group). CMVIG reduced the rate of severe CMV-associated disease in patients undergoing orthotopic liver transplantation. No effect of CMVIG on CMV donor-positive, recipient-negative liver transplant recipients was shown, suggesting a need for additional prophylactic strategies.

(PDF emailed within 1 workday: $29.90)

Accession: 045696804

Download citation: RISBibTeXText

PMID: 8214995

Related references

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 2018, 2018

A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation. Hepatology 21(2): 366-372, 1995

A double-blind placebo-controlled randomized trial of prostaglandin E-1 in liver transplantation. Hepatology 18(4 PART 2): 58A, 1993

Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 128(12 Pt 1): 975-981, 1998

Bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Liver Transplantation 12(7): 1168-1169, 2006

A randomized double blind controlled trial of tranexamic acid prophylaxis during liver transplantation. Anesthesiology 81(3A): A1287, 1994

A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity. American Journal of Tropical Medicine and Hygiene 88(1): 172-177, 2013

A randomized double blind placebo controlled trial of oral and intravenous acyclovir for the prevention of cytomegalovirus and herpes simplex virus following cardiac transplantation. Journal of Heart & Lung Transplantation 13(1 PART 2): S60, 1994

Medical research council trial of antilymphocyte globulin in renal transplantation. A multicenter randomized double-blind placebo controlled clinical investigation. Transplantation 35(6): 539-545, 1983

A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Medicine 5(3): 140-143, 2004

Effects of continuous use of probiotics before liver transplantation: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition 36(6): 1530-1539, 2017

Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo. European Journal of Gastroenterology and Hepatology 30(8): 951-958, 2018

Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 144(4): 239-248, 2006

Perioperative prostaglandin e1 infusion in living donor liver transplantation: A double-blind, placebo-controlled randomized trial. Liver Transplantation 22(8): 1067-1074, 2017

Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biology of Blood and Marrow Transplantation 24(11): 2216-2223, 2018